Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme

Hartwig P. Huemer; Birgit Strobl; Norbert Nowotny

doi:10.1016/S0264-410X(99)00413-2

Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme

Hartwig P. Huemer^*, Birgit Strobl, Norbert Nowotny

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

The nonreplicating chicken adapted vaccinia virus strain MVA was used in a combined vaccine scheme. Using the equine herpesvirus type 1 (EHV-1) encoded complement-receptor glycoprotein C as antigen, only poor antibody response was induced by exclusive vaccination with DNA plasmids. The administration of recombinant MVA followed by plasmid immunization elicited both humoral and cellular immune responses in hamster comparable to EHV-1 full virus vaccines. Our results indicate that recombinant constructs based on MVA represent a safe and efficient way to overcome problems of poor immunogenicity of certain antigens upon intramuscular DNA vaccination, thus replacing sophisticated adjuvants or application methods, which are not readily applicable in routine practice.

Original language	English
Pages (from-to)	1320-1326
Number of pages	7
Journal	Vaccine
Volume	18
Issue number	14
DOIs	https://doi.org/10.1016/S0264-410X(99)00413-2
Publication status	Published - Feb 4 2000
Externally published	Yes

Keywords

DNA vaccine
EHV
MVA
Vaccinia virus

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/S0264-410X(99)00413-2

Cite this

@article{444499cf5d1643568778f340b1ba0185,

title = "Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme",

abstract = "The nonreplicating chicken adapted vaccinia virus strain MVA was used in a combined vaccine scheme. Using the equine herpesvirus type 1 (EHV-1) encoded complement-receptor glycoprotein C as antigen, only poor antibody response was induced by exclusive vaccination with DNA plasmids. The administration of recombinant MVA followed by plasmid immunization elicited both humoral and cellular immune responses in hamster comparable to EHV-1 full virus vaccines. Our results indicate that recombinant constructs based on MVA represent a safe and efficient way to overcome problems of poor immunogenicity of certain antigens upon intramuscular DNA vaccination, thus replacing sophisticated adjuvants or application methods, which are not readily applicable in routine practice.",

keywords = "DNA vaccine, EHV, MVA, Vaccinia virus",

author = "Huemer, {Hartwig P.} and Birgit Strobl and Norbert Nowotny",

note = "Funding Information: The authors appreciated the help of Professor H. Walln{\"o}fer with the animal experiments. PD Dr. C.P. Cerny, LMU Munich, Germany and Dr. H. Shida, University of Kyoto, Japan are gratefully acknowledged for reagent donation as well as R. Stangl from Canberra Packard for the supply of the luminescence equipment and reagents. The work has been supported by the Austrian Academy of Sciences program for the advancement of research and technology (APART) and the Jubil{\"a}umsfonds of the Austrian National Bank.",

year = "2000",

month = feb,

day = "4",

doi = "10.1016/S0264-410X(99)00413-2",

language = "English",

volume = "18",

pages = "1320--1326",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "14",

}

TY - JOUR

T1 - Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme

AU - Huemer, Hartwig P.

AU - Strobl, Birgit

AU - Nowotny, Norbert

N1 - Funding Information: The authors appreciated the help of Professor H. Wallnöfer with the animal experiments. PD Dr. C.P. Cerny, LMU Munich, Germany and Dr. H. Shida, University of Kyoto, Japan are gratefully acknowledged for reagent donation as well as R. Stangl from Canberra Packard for the supply of the luminescence equipment and reagents. The work has been supported by the Austrian Academy of Sciences program for the advancement of research and technology (APART) and the Jubiläumsfonds of the Austrian National Bank.

PY - 2000/2/4

Y1 - 2000/2/4

N2 - The nonreplicating chicken adapted vaccinia virus strain MVA was used in a combined vaccine scheme. Using the equine herpesvirus type 1 (EHV-1) encoded complement-receptor glycoprotein C as antigen, only poor antibody response was induced by exclusive vaccination with DNA plasmids. The administration of recombinant MVA followed by plasmid immunization elicited both humoral and cellular immune responses in hamster comparable to EHV-1 full virus vaccines. Our results indicate that recombinant constructs based on MVA represent a safe and efficient way to overcome problems of poor immunogenicity of certain antigens upon intramuscular DNA vaccination, thus replacing sophisticated adjuvants or application methods, which are not readily applicable in routine practice.

AB - The nonreplicating chicken adapted vaccinia virus strain MVA was used in a combined vaccine scheme. Using the equine herpesvirus type 1 (EHV-1) encoded complement-receptor glycoprotein C as antigen, only poor antibody response was induced by exclusive vaccination with DNA plasmids. The administration of recombinant MVA followed by plasmid immunization elicited both humoral and cellular immune responses in hamster comparable to EHV-1 full virus vaccines. Our results indicate that recombinant constructs based on MVA represent a safe and efficient way to overcome problems of poor immunogenicity of certain antigens upon intramuscular DNA vaccination, thus replacing sophisticated adjuvants or application methods, which are not readily applicable in routine practice.

KW - DNA vaccine

KW - EHV

KW - MVA

KW - Vaccinia virus

UR - http://www.scopus.com/inward/record.url?scp=0033957536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033957536&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(99)00413-2

DO - 10.1016/S0264-410X(99)00413-2

M3 - Article

C2 - 10618528

AN - SCOPUS:0033957536

SN - 0264-410X

VL - 18

SP - 1320

EP - 1326

JO - Vaccine

JF - Vaccine

IS - 14

ER -

Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this